Trial Profile
Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Peptide vaccines (Primary) ; Peptide vaccines (Primary) ; Varlilumab (Primary) ; Montanide ISA-51; Montanide ISA-51; Poly ICLC; Poly ICLC
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics
- Acronyms Mel-65
- 02 Feb 2024 Status changed from recruiting to completed.
- 03 Apr 2023 Planned End Date changed from 8 Feb 2023 to 8 Sep 2024.
- 03 Apr 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Sep 2023.